Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
McKinsey
AstraZeneca
Boehringer Ingelheim
Harvard Business School

Last Updated: May 19, 2022

CLINICAL TRIALS PROFILE FOR ZOLMITRIPTAN


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Zolmitriptan

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00382993 ↗ A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2) Completed GlaxoSmithKline Phase 3 2006-12-01 This is a randomized, double-blind, placebo-controlled, crossover, two-attack, out-patient, early-intervention evaluation of subjects who have migraine with or without aura and who discontinued use of short acting triptan(s) within the past year due to non-response or intolerance. Subjects will treat 2 separate migraine attacks during the mild phase of each attack; one attack will be treated with one tablet of the Combination Product (sumatriptan succinate and naproxen sodium) and the other attack with one tablet of placebo (crossover design). [Study 2 of 2]
NCT00383162 ↗ A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2) Completed GlaxoSmithKline Phase 3 2006-11-01 This is a randomized, double-blind, placebo-controlled, crossover, two-attack, out-patient, early-intervention evaluation of subjects who have migraine with or without aura and who discontinued use of short acting triptan(s) within the past year due to non-response or intolerance. Subjects will treat 2 separate migraine attacks during the mild phase of each attack; one attack will be treated with one tablet of the Combination Product (sumatriptan succinate and naproxen sodium) and the other attack with one tablet of placebo (crossover design). [Study 1 of 2]
NCT00617695 ↗ Efficacy of Zolmitriptan (Zomig) in the Treatment of Migraines in Adolescents Completed AstraZeneca Phase 3 2003-09-01 The purpose of this study is to evaluate the effectiveness and safety of Zolmitriptan (Zomig) nasal spray, 5.0 mg, compared with placebo (inactive drug) for 2 migraine headaches over a 3-month period in adolescent patients (aged 12 to 17 years) with migraine headaches
NCT00617747 ↗ Efficacy and Tolerability of Zolmitriptan Nasal Spray Completed AstraZeneca Phase 3 2002-09-01 The purpose of this study is to evaluate the effectiveness and tolerability (the ability not to experience ill effects from the study drug) of a zolmitriptan nasal spray, 5.0 mg, compared with placebo (inactive drug) for 2 migraine headaches for up to 12 weeks in adult subjects with migraine headaches
NCT00637286 ↗ ZAP, US. Zomig for Appropriate for Primary Care Completed AstraZeneca Phase 4 2004-07-01 The purpose of this study is to determine how useful and effective the use of ZOMIG-ZMT™ (zolmitriptan) 5.0 mg and ZOMIG® Nasal Spray (zolmitriptan) 5.0 mg is for patients, in treating migraine over a period of 6 months
NCT01085123 ↗ Determine Central 5-HT1B Receptor Occupancy of ZOMIG® Rapimelt (Zolmitriptan) in Healthy Male Volunteers Completed AstraZeneca Phase 1 2010-05-01 The purpose of this study is to determine the central 5-HT1B receptor occupancy of ZOMIG® Rapimelt (zolmitriptan) in healthy male volunteers.
NCT01211145 ↗ Zomig - Treatment of Acute Migraine Headache in Adolescents Completed AstraZeneca Phase 4 2010-09-01 The purpose of this study is to investigate if Zomig® Nasal Spray will help children (age 12-17 years) with migraine headaches feel better. This will be done by comparing 3 different doses of Zomig Nasal Spray with placebo nasal spray (inactive treatment).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Zolmitriptan

Condition Name

Condition Name for Zolmitriptan
Intervention Trials
Migraine 12
Migraine With or Without Aura 2
Acute Migraine 2
Cluster Headache 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Zolmitriptan
Intervention Trials
Migraine Disorders 14
Headache 5
Cluster Headache 2
Premature Birth 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Zolmitriptan

Trials by Country

Trials by Country for Zolmitriptan
Location Trials
United States 136
Poland 1
United Kingdom 1
Estonia 1
Latvia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Zolmitriptan
Location Trials
Texas 10
California 8
Florida 7
New York 6
Missouri 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Zolmitriptan

Clinical Trial Phase

Clinical Trial Phase for Zolmitriptan
Clinical Trial Phase Trials
Phase 4 4
Phase 3 6
Phase 2/Phase 3 2
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Zolmitriptan
Clinical Trial Phase Trials
Completed 18
Unknown status 3
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Zolmitriptan

Sponsor Name

Sponsor Name for Zolmitriptan
Sponsor Trials
Zosano Pharma Corporation 6
AstraZeneca 6
Acorda Therapeutics 2
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Zolmitriptan
Sponsor Trials
Industry 21
Other 5
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Express Scripts
Dow
Baxter
Medtronic
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.